EA Pharma Co., Ltd Sustainability Profile
EA Pharma Co., Ltd., headquartered in Japan, is a prominent player in the pharmaceutical industry, specialising in the development and manufacturing of innovative gastrointestinal treatments. Founded in 2015, the company has quickly established itself as a leader in its field, focusing on prescription medications that address unmet medical needs. With a strong operational presence in Asia and beyond, EA Pharma is dedicated to enhancing patient outcomes through its unique product offerings, which include advanced formulations and targeted therapies. The company’s commitment to research and development has led to significant milestones, positioning it as a trusted name in the healthcare sector. EA Pharma's dedication to quality and innovation continues to drive its success and reputation in the competitive pharmaceutical landscape.
DitchCarbon Score
How does EA Pharma Co., Ltd's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
EA Pharma Co., Ltd's score of 37 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
EA Pharma Co., Ltd, headquartered in Japan, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Eisai Co., Ltd., which provides emissions data and climate commitments cascaded from its parent organisation. Eisai Co., Ltd. has set various climate initiatives, including targets under the Science Based Targets initiative (SBTi), and participates in the Carbon Disclosure Project (CDP) and RE100, which focuses on renewable energy commitments. However, specific reduction targets or achievements for EA Pharma Co., Ltd. are not detailed in the available information. As a subsidiary, EA Pharma's climate commitments are aligned with those of Eisai, reflecting a broader industry commitment to reducing carbon emissions and enhancing sustainability practices. The absence of specific emissions data highlights the need for ongoing transparency and accountability in corporate climate strategies.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 49,457,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 55,830,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 456,386,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is EA Pharma Co., Ltd's Industry?
How Carbon Intensive is EA Pharma Co., Ltd's Location?
EA Pharma Co., Ltd's Scope 3 Categories Breakdown
EA Pharma Co., Ltd's Scope 3 emissions, which decreased by 6% last year and increased by approximately 24% since 2019, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" representing nearly all of their reported Scope 3 footprint.
Top Scope 3 Categories
EA Pharma Co., Ltd's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
EA Pharma Co., Ltd has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
